相关实验视频

Updated: May 20, 2025

Identifying PD-1/PD-L1 Inhibitors with Surface Plasmon Resonance Technology

Identifying PD-1/PD-L1 Inhibitors with Surface Plasmon Resonance Technology

Published on: May 2, 2025

MDSC检查点阻塞疗法:在癌症免疫疗法中克服免疫抑制的新突破点

Abdulrahman Ibrahim^1,2, Nada Mohamady Farouk Abdalsalam^1,2, Zihao Liang¹

¹Guangdong Immune Cell Therapy Engineering and Technology Research Center, Center for Protein and Cell-Based Drugs, Institute of Biomedicine and Biotechnology, Shenzhen Institute of Advanced Technology, Chinese Academy of Sciences, 518055, Shenzhen, China.

Cancer gene therapy

|March 27, 2025

概括

骨髓系衍生抑制细胞 (MDSCs) 阻碍了癌症免疫疗法在固体瘤. 将MDSC检查点封锁与其他疗法相结合,有望克服这些障碍并提高治疗效率.

科学领域:

在瘤学瘤学.
免疫学免疫学免疫学
癌症生物学癌症生物学

背景情况:

癌症免疫疗法在血液癌症中有效,但由于免疫抑制性瘤微环境 (TME),在固体瘤中受到限制.
骨髓衍生抑制细胞 (MDSC) 是TME的关键参与者,抑制抗瘤免疫力,并通过非免疫路径促进瘤进展,如血管生成和上皮-介质酶过渡 (EMT).

研究的目的:

审查MDSCs在固体瘤中的双重作用.
为了强调未经探索的MDSC检查点封锁策略.
讨论涉及MDSCs的组合免疫疗法,以加强癌症治疗.

主要方法:

文献审查侧重于MDSC功能和治疗策略.
对当前和新兴的MDSC向疗法的分析.
讨论与免疫疗法结合的方法.

主要成果:

MDSCs通过免疫和非免疫机制促进免疫抑制和瘤进展.
仅仅针对MDSC的目标已经显示出有限的成功.
与其他免疫疗法相结合的MDSC检查点封锁是克服治疗障碍的有希望的策略.

结论:

在固体瘤中,MDSC对有效的癌症免疫疗法提出了重大挑战.
MDSC检查点封锁策略,特别是在组合疗法中,提供了一种潜在的途径,以提高治疗疗效.
需要进一步的研究来优化针对MDSC的组合免疫疗法,以治疗固体瘤.

更多相关视频

Analysis of Human T Cell Activity in an Allogeneic Co-Culture Setting of Pre-Treated Tumor Cells

Analysis of Human T Cell Activity in an Allogeneic Co-Culture Setting of Pre-Treated Tumor Cells

Published on: March 7, 2025

Monitoring PD-1-Blocking Antibodies Bound to T Cells Derived from a Drop of Peripheral Blood

Monitoring PD-1-Blocking Antibodies Bound to T Cells Derived from a Drop of Peripheral Blood

Published on: February 5, 2020

相关概念视频

Tumor Immunotherapy

Tumor Immunotherapy

Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.

Mitogens and the Cell Cycle

Mitogens and the Cell Cycle

Mitogens and their receptors play a crucial role in controlling the progression of the cell cycle. However, the loss of mitogenic control over cell division leads to tumor formation. Therefore, mitogens and mitogen receptors play an important role in cancer research. For instance, the epidermal growth factor (EGF) - a type of mitogen and its transmembrane receptor (EGFR), decides the fate of the cell's proliferation. When EGF binds to EGFR, a member of the ErbB family of tyrosine kinase...